Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D.
Harrington KJ, et al.
J Clin Oncol. 2023 Feb 1;41(4):790-802. doi: 10.1200/JCO.21.02508. Epub 2022 Oct 11.
J Clin Oncol. 2023.
PMID: 36219809
Free PMC article.
Clinical Trial.
Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS 1 (HR, 0.64; 95% CI, 0.53 to 0.78), and total (HR, 0.71; 95% CI, 0.59 to 0.85) populations. The objective response rate on second-course pembrolizumab was 27 …
Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS 1 (HR, 0.64; 95% CI, 0.5 …